Cited by 337Drug Transport and Resistance MechanismsPharmacogenetics and Drug MetabolismProtein Interaction Studies and Fluorescence Analysis

The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.

EVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS

Shitara, Yoshihisa, Sato, Hitoshi, Sugiyama, Yuichi·2005·Annual Review of Pharmacology and Toxicology

DOI 10.1146/annurev.pharmtox.44.101802.121444

Open this paper in CoChat — free account

Abstract

Recent studies have revealed the import role played by transporters in the renal and hepatobiliary excretion of many drugs. These transporters exhibit a broad substrate specificity with a degree of overlap, suggesting the possibility of transporter-mediated drug-drug interactions with other substrates. This review is an overview of the roles of transporters and the possibility of transporter-mediated drug-drug interactions. Among the large number of transporters, we compare the Ki values of inhibitors for organic anion transporting polypeptides (OATPs) and organic anion transporters (OATs) and their therapeutic unbound concentrations. Among them, cephalosporins and probenecid have the potential to produce clinically relevant OAT-mediated drug-drug interactions, whereas cyclosporin A and rifampicin may trigger OATP-mediated ones. These drugs have been reported to cause drug-drug interactions in vivo with OATs or OATP substrates, suggesting the possibility of transporter-mediated drug-drug interactions. To avoid adverse consequences of such transporter-mediated drug-drug interactions, we need to be more aware of the role played by drug transporters as well as those caused by drug metabolizing enzymes.

Integrity signals

Registry

Crossref · 10.1146/annurev.pharmtox.44.101802.121444

Cites

199 of 199 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T. A., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,372
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4028 · Cited by 937
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
Miyake, K., Mickley, L. A., Litman, T., Zhan, Z., Robey, R. W., Cristensen, B., Brangi, M., Greenberger, L., Dean, M. C., Fojo, T., et al. (1999) · PubMed · Cited by 819
Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene
Paulusma, C. C., Bosma, P. J., Zaman, G. J. R., Bakker, C., Otter, M. Y., Scheffer, G. L., Scheper, R. J., Borst, P., & Elferink, R. P. J. O. (1996) · Science · doi:10.1126/science.271.5252.1126 · Cited by 817
A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.
Allikmets, R., Schriml, L. M., Hutchinson, A. A., Romano-Spica, V., & Dean, M. C. (1998) · PubMed · Cited by 798
Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance
Pang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797
Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance
König, J., Nies, A. T., Cui, Y., Leier, I., & KEPPLER, D. O. R. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00169-8 · Cited by 786
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver
Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K. E., Meier, P. J., & Hagenbuch, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.21176 · Cited by 718
Molecular and Functional Identification of Sodium Ion-dependent, High Affinity Human Carnitine Transporter OCTN2
Tamai, I., Ohashi, R., Nezu, J., Yabuuchi, H., Oku, A., Shimane, M., Sai, Y., & Tsuji, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20378 · Cited by 696

Show all 199 references

Research works printed but not linked: 52

Pang KS, 1978, J. Pharmacol. Exp. Ther., 207, 178
Lecureur V, 2000, Mol. Pharmacol., 57, 24
Yamazaki M, 2001, J. Pharmacol. Exp. Ther., 296, 723
Walle UK, 1998, Drug Metab. Dispos., 26, 343
Tanigawara Y, 1992, J. Pharmacol. Exp. Ther., 263, 840
Zhang L, 1998, J. Pharmacol. Exp. Ther., 286, 354
Yabuuchi H, 1999, J. Pharmacol. Exp. Ther., 289, 768
Wu X, 1999, J. Pharmacol. Exp. Ther., 290, 1482
Ohashi R, 1999, J. Pharmacol. Exp. Ther., 291, 778
Nakai D, 2001, J. Pharmacol. Exp. Ther., 297, 861
Ishizuka H, 1998, J. Pharmacol. Exp. Ther., 287, 37
Hosokawa S, 1992, Lab. Animal Sci., 42, 27
Muller M, 1997, Am. J. Physiol., 272, G1285
10.1016/0304-4157(95)00006-D · DOI
Taniguchi K, Cancer Res., 56, 4124
Kuwano M, 1999, Anticancer Drug Des., 14, 123
Niinuma K, 1999, Am. J. Physiol, 276, G1153
Cui Y, 1999, Mol. Pharmacol., 55, 929
Niinuma K, 1999, Am. J. Physiol, 276, G1153
Hooijberg JH, 1999, Cancer Res., 59, 2532
Zeng H, 2000, Cancer Res., 60, 4779
Allikmets R, 1998, Cancer Res., 58, 5337
Miyake K, 1999, Cancer Res., 59, 8
Maliepaard M, 2001, Cancer Res., 61, 3458
Akhteruzzaman S, 1999, J. Pharmacol. Exp. Ther., 290, 1107
Madan A, 1999, Drug Metab. Dispos., 27, 327
Kouzuki H, 1998, J. Pharmacol. Exp. Ther., 286, 1043
Kouzuki H, 1999, J. Pharmacol. Exp. Ther, 288, 627
Ito K, 1998, Pharmacol. Rev., 50, 387
Ueda K, 2001, J. Pharmacol. Exp. Ther., 297, 1036
Masuda S, 1997, J. Pharmacol. Exp. Ther., 283, 1039
Masuda S, 1999, Mol. Pharmacol., 55, 743
Takeuchi A, 2001, J. Pharmacol. Exp. Ther., 299, 261
Chu XY, 1997, J. Pharmacol. Exp. Ther., 281, 304
Gupta E, 1994, Cancer Res., 54, 3723
Regazzi MB, 1993, Transplant. Proc., 25, 2732
Hasunuma T, 2003, J. Clin. Ther. Med., 19, 381
10.1345/aph.1A116 · DOI
Mueck W, 2001, AAPS PharmSci., 3, 3566
Sallustio BC, 1996, Drug Metab. Dispos., 24, 984
Sabordo L, 1998, J. Pharmacol. Exp. Ther., 288, 414
Sabordo L, 2000, J. Pharmacol. Exp. Ther., 295, 44
Olinga P, 1998, J. Pharmacol. Exp. Ther., 285, 506
Marino EL, 1981, Int. J. Clin. Pharmacol. Ther. Toxicol., 19, 506
Kremer JM, 1995, J. Rheumatol., 22, 2072
Apiwattanakul N, 1999, Mol. Pharmacol., 55, 847
Morita N, 2001, J. Pharmacol. Exp. Ther., 298, 1179
Jariyawat S, 1999, J. Pharmacol. Exp. Ther, 290, 672
Uwai Y, 2000, J. Pharmacol. Exp. Ther., 295, 261
Cvetkovic M, 1999, Drug Metab. Dispos., 27, 866
Bossuyt X, 1996, J. Pharmacol. Exp. Ther., 276, 891–96
Sugiyama D, 2001, J. Pharmacol. Exp. Ther., 298, 316–22

Sorted by citations

Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citation
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citation
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Neuvonen, P. J., Niemi, M., & Backman, J. T. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 874
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Coexistence of passive and carrier-mediated processes in drug transport
Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G. F., Faller, B., Fischer, H., Gerebtzoff, G., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3187 · Cited by 672
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 631
Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines
Hilgendorf, C., Ahlin, G., Seithel‐Keuth, A., Artursson, P., Ungell, A.-L. B., & Karlsson, J. E. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.014902 · Cited by 592
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 583
Self-citation
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 595
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 494
Self-citation
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
Dobson, P. D., & Kell, D. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2438 · Cited by 475
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family
Hagenbuch, B., & Gui, C. (2008) · Xenobiotica · doi:10.1080/00498250801986951 · Cited by 410
New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process
Huang, S. M., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S. C., Temple, R., Abraham, S., Al-Habet, S. M. H., Baweja, R. K., Burckart, G. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312153 · Cited by 396
A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES
Riley, R. J., McGinnity, D. F., & Austin, R. P. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004259 · Cited by 382
Drug transport by Organic Anion Transporters (OATs)
Burckhardt, G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.010 · Cited by 359
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Differential Regulation of Sinusoidal and Canalicular Hepatic Drug Transporter Expression by Xenobiotics Activating Drug-Sensing Receptors in Primary Human Hepatocytes
Jigorel, É., Vée, M. L., Boursier-Neyret, C., Parmentier, Y., & Fardel, O. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010033 · Cited by 322
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
Self-citation
Effects of renal failure on drug transport and metabolism
Sun, H., Frassetto, L. A., & Benet, L. Z. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.010 · Cited by 297
In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises
Miners, J. O., Knights, K., Houston, J. B., & Mackenzie, P. I. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.019 · Cited by 227
In vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney
Kusuhara, H., & Sugiyama, Y. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.37 · Cited by 221
Self-citation
Renal Drug Transporters and Drug Interactions
Ivanyuk, A., Livio, F., Biollaz, J., & Buclin, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0506-8 · Cited by 233
Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin
Neuvonen, P. J., Backman, J. T., & Niemi, M. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847070-00003 · Cited by 217
Physicochemical Determinants of Human Renal Clearance
Varma, M. V. S., Feng, B., Obach, R. S., Troutman, M. D., Chupka, J., Miller, H., & El‐Kattan, A. F. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900403j · Cited by 216
Organic Anion Transporter Family: Current Knowledge
Anzai, N., Kanai, Y., & Endou, H. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj06006x · Cited by 209
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril
Maeda, K., Ieiri, I., YASUDA, K., FUJINO, A., FUJIWARA, H., OTSUBO, K., HIRANO, M., Watanabe, T., Kitamura, Y., & Kusuhara, H. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.011 · Cited by 201
In Vitro and In Vivo Evidence of the Importance of Organic Anion Transporters (OATs) in Drug Therapy
Burckhardt, G., & Burckhardt, B. C. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-14541-4_2 · Cited by 199
Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells
Tsuda, M., Terada, T., Ueba, M., Sato, T., Masuda, S., Katsura, T., & Inui, K. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147918 · Cited by 194
Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line
Vée, M. L., Jigorel, É., Glaise, D., Gripon, P., Guguen‐Guillouzo, C., & Fardel, O. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.004 · Cited by 189
A regulatory viewpoint on transporter-based drug interactions
Zhang, L., Zhang, Y. (. )., Strong, J. M., Reynolds, K. S., & Huang, S. M. (2008) · Xenobiotica · doi:10.1080/00498250802017715 · Cited by 187
Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein
Chu, X., Bleasby, K., Yabut, J. A., Cai, X., Chan, G. H., Hafey, M. J., Xu, S. S., Bergman, A. J., Braun, M. P., Dean, D. C., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.116517 · Cited by 179
Transporter-Mediated Drug–Drug Interactions
Müller, F., & Fromm, M. F. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.44 · Cited by 178
A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters
Tahara, H., Kusuhara, H., Endou, H., Koepsell, H., Imaoka, T., Fuse, E., & Sugiyama, Y. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.088104 · Cited by 171
Self-citation
Absorption, Disposition, and Pharmacokinetics of Saponins from Chinese Medicinal Herbs: What Do We Know and What Do We Need to Know More?
Yu, K., Chen, F., & Li, C. (2012) · Current Drug Metabolism · doi:10.2174/1389200211209050577 · Cited by 165
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Beavers, C. J., Rodgers, J. E., Bagnola, A. J., Beckie, T. M., Campia, U., Palo, K. E. D., Okwuosa, T. M., Przespolewski, E. R., & Sj, D. (2022) · Circulation · doi:10.1161/cir.0000000000001056 · Cited by 170
Valproic Acid Is Not a Substrate for P-glycoprotein or Multidrug Resistance Proteins 1 and 2 in a Number of in Vitro and in Vivo Transport Assays
Baltes, S., Fedrowitz, M., Luna‐Tortós, C., Potschka, H., & Löscher, W. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102491 · Cited by 159
Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices
Nozaki, Y., Kusuhara, H., Kondo, T., Iwaki, M., Shiroyanagi, Y., Nakayama, H., Horita, S., Nakazawa, H., Okano, T., & Sugiyama, Y. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121491 · Cited by 158
Self-citation
Scientific Perspectives on Drug Transporters and Their Role in Drug Interactions
Zhang, L., Strong, J. M., Qiu, W., Lesko, L. J., & Huang, S. M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050095h · Cited by 153
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.429 · Cited by 148
Drug transporters in the lung—do they play a role in the biopharmaceutics of inhaled drugs?
Bosquillon, C. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21995 · Cited by 148
Effects of Drug Transporters on Volume of Distribution
Grover, A., & Benet, L. Z. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9102-7 · Cited by 142
Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions
Izumi, S., Nozaki, Y., Maeda, K., Komori, T., Takenaka, O., Kusuhara, H., & Sugiyama, Y. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059105 · Cited by 143
Self-citation
Assessment of the Role of Renal Organic Anion Transporters in Drug-Induced Nephrotoxicity
Hagos, Y., & Wolff, N. A. (2010) · Toxins · doi:10.3390/toxins2082055 · Cited by 126
Drug interactions evaluation: An integrated part of risk assessment of therapeutics
Zhang, L., Reynolds, K. S., Zhao, P., & Huang, S.-M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.016 · Cited by 125
Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP
Gameiro, M., Silva, R. V. D. S., Rocha‐Pereira, C., Carmo, H., Carvalho, F. D., Bastos, M. D. L., & Remião, F. (2017) · Molecules · doi:10.3390/molecules22040600 · Cited by 129
Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms
Yoshida, K. J., Maeda, K., & Sugiyama, Y. (2012) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140309 · Cited by 123
Self-citation
Uptake of Cardiovascular Drugs Into the Human Heart
Grube, M., zu Schwabedissen, H. E. M., Präger, D., Haney, J., Möritz, K.-U., Meissner, K., Rosskopf, D., Eckel, L., Böhm, M., Jedlitschky, G., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.586107 · Cited by 118
Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics
Moriyama, Y., Hiasa, M., Matsumoto, T., & Omote, H. (2008) · Xenobiotica · doi:10.1080/00498250701883753 · Cited by 116
Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) Transporters in the Intestine, Liver and Kidney
Zaïr, Z. M., Eloranta, J. J., Stieger, B., & Kullak-Ublick, G. A. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.597 · Cited by 114
Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human
Li, M., Yuan, H., Li, N., Song, G., Zheng, Y. Z., Baratta, M., Hua, F., Thurston, A., Wang, J., & Lai, Y. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.06.008 · Cited by 111
Prediction of Fluoroquinolone-Induced Elevation in Serum Creatinine Levels: A Case of Drug–Endogenous Substance Interaction Involving the Inhibition of Renal Secretion
Imamura, Y., Murayama, N., Okudaira, N., Kurihara, A., Okazaki, O., Izumi, T., Inoue, K., Yuasa, H., Kusuhara, H., & Sugiyama, Y. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.232 · Cited by 108
Self-citation
Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes
Paine, S. W., Parker, A. J., Gardiner, P., Webborn, P. J. H., & Riley, R. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019455 · Cited by 105
PET Imaging–Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me
Takashima, T., Kitamura, S., Wada, Y., Tanaka, M., Shigihara, Y., Ishii, H., Ijuin, R., Shiomi, S., Nakae, T., Watanabe, Y., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098681 · Cited by 105
Self-citation
FUNCTIONAL EXPRESSION OF SINUSOIDAL DRUG TRANSPORTERS IN PRIMARY HUMAN AND RAT HEPATOCYTES
Jigorel, É., Vée, M. L., Boursier-Neyret, C., Bertrand, M., & Fardel, O. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004762 · Cited by 105
Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state
Feng, B., LaPerle, J. L., Chang, G., & Varma, M. V. S. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.482930 · Cited by 106
Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase
Fujino, H., Saito, T., Ogawa, S.-I., & Kojima, J. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.57.10.0009 · Cited by 104
The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine
Matsushima, S., Maeda, K., Inoue, K., Ohta, K., Yuasa, H., Kondo, T., Nakayama, H., Horita, S., Kusuhara, H., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023911 · Cited by 104
Self-citation
The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?
Chu, X., Bleasby, K., Chan, G. H., Nunes, I., & Evers, R. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067694 · Cited by 102
Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein
Izumi, S., Nozaki, Y., Komori, T., Maeda, K., Takenaka, O., Kusano, K., Yoshimura, T., Kusuhara, H., & Sugiyama, Y. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052290 · Cited by 99
Self-citation
Absolute Difference of Hepatobiliary Transporter Multidrug Resistance-Associated Protein (MRP2/Mrp2) in Liver Tissues and Isolated Hepatocytes from Rat, Dog, Monkey, and Human
Li, N., Zhang, Y., Hua, F., & Lai, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023234 · Cited by 95
Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans
Maeda, K., Tian, Y., Fujita, T., Ikeda, Y., Kumagai, Y., Kondo, T., Tanabe, K., Nakayama, H., Horita, S., Kusuhara, H., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.04.004 · Cited by 94
Self-citation
The role of hepatic transporters in drug elimination
Funk, C. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.363 · Cited by 92
Transporter-mediated drug interactions: clinical implications andin vitroassessment
Lin, J. H. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.1.81 · Cited by 90
Renal Disposition of Colistin in the Isolated Perfused Rat Kidney
Ma, Z., Wang, J., Nation, R. L., Li, J., Turnidge, J. D., Coulthard, K. P., & Milne, R. W. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00030-09 · Cited by 89
Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans
Matsushima, S., Maeda, K., Ishiguro, N., Igarashi, T., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017814 · Cited by 88
Self-citation
Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1
Dreiseitel, A., Oosterhuis, B., Krisztina, V., Schreier, P. H., Oehme, A., Locher, S., Hajak, G., & Sand, P. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00495.x · Cited by 87
Impact of Genetic Knockout of PEPT2 on Cefadroxil Pharmacokinetics, Renal Tubular Reabsorption, and Brain Penetration in Mice
Shen, H., Ocheltree, S. M., Hu, Y., Keep, R. F., & Smith, D. E. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015263 · Cited by 86
Drugdrug interactions involving membrane transporters in the human kidney
Li, M., Anderson, G. D., & Wang, J. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.4.505 · Cited by 84
Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues
Nigám, S. K., Bush, K. T., & Bhatnagar, V. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0558 · Cited by 83
Quantitative Expression Profile of Hepatobiliary Transporters in Sandwich Cultured Rat and Human Hepatocytes
Li, N., Bi, Y., Duignan, D. B., & Lai, Y. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900044x · Cited by 82
Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data
Poirier, A., Cascais, A., Funk, C., & Lavé, T. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9139-3 · Cited by 80
Toxin mixture in cyanobacterial blooms – a critical comparison of reality with current procedures employed in human health risk assessment
Dietrich, D. R., Fischer, A., Michel, C., & Hoeger, S. (2008) · Springer eBooks · doi:10.1007/978-0-387-75865-7_39 · Cited by 77
Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling
Choi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 79
“In the disposition process, transporters and enzymes play a key role by interacting with each other [86].”
Background
Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug interactions
Camenisch, G., & Umehara, K. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1784 · Cited by 76
Prediction of human pharmacokinetics — renal metabolic and excretion clearance
Fagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.11.0002 · Cited by 76
Pannexin 1 Constitutes the Large Conductance Cation Channel of Cardiac Myocytes
Kienitz, M., Bender, K., Dermietzel, R., Pott, L., & Zoidl, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.163477 · Cited by 76
N-glycosylation Dictates Proper Processing of Organic Anion Transporting Polypeptide 1B1
Yao, J., Hong, W., Huang, J., Zhan, K., Huang, H., & Hong, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052563 · Cited by 72
Involvement of Multidrug Resistance-Associated Protein 2 (Abcc2) in Molecular Weight-Dependent Biliary Excretion of β-Lactam Antibiotics
Kato, Y., Takahara, S., Kato, S., Kubo, Y., Sai, Y., Tamai, I., Yabuuchi, H., & Tsuji, A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019125 · Cited by 72
Scientific and Regulatory Perspectives on Metabolizing Enzyme−Transporter Interplay and Its Role in Drug Interactions: Challenges in Predicting Drug Interactions
Zhang, L., Zhang, Y., & Huang, S. M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900132e · Cited by 71
Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments
Watanabe, T., Maeda, K., Kondo, T., Nakayama, H., Horita, S., Kusuhara, H., & Sugiyama, Y. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.026062 · Cited by 70
Self-citation
Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans
Nakagomi, R., Nakai, D., & Tokui, T. (2007) · Xenobiotica · doi:10.1080/00498250601188808 · Cited by 70
Pharmacokinetic Interactions Between Statins and Fibrates
Corsini, A., Bellosta, S., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.007 · Cited by 69
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab‐Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
Xu, Y. Y., Hijazi, Y., Wolf, A., Wu, B. M., Sun, Y., & Zhu, M. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12003 · Cited by 69
Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia
Budinski, D., Arneson, V., Hounslow, N. J., & Gratsiansky, N. A. (2009) · Clinical Lipidology · doi:10.2217/clp.09.20 · Cited by 68
INTERACTIONS OF AMOXICILLIN AND CEFACLOR WITH HUMAN RENAL ORGANIC ANION AND PEPTIDE TRANSPORTERS
Li, M., Anderson, G. D., Phillips, B., Kong, W., Shen, D. D., & Wang, J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006791 · Cited by 67
P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate
Jia, Y., Liu, Z., Wang, C., Meng, Q., Huo, X., Liu, Q., Sun, H., Sun, P., Yang, X., Ma, X., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.06.030 · Cited by 67
Impact of Hepatic Uptake Transporters on Pharmacokinetics and Drug−Drug Interactions: Use of Assays and Models for Decision Making in the Pharmaceutical Industry
Soars, M. G., Webborn, P. J. H., & Riley, R. J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800246x · Cited by 66
Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone
Ahn, S.-S., Ohtomo, S., Kiyokawa, J., Nakagawa, T., Yamane, M., Lee, K. J., Kim, K. H., Kim, B. H., Tanaka, J., Kawabe, Y., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.231647 · Cited by 66
In vitro-in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects
Webborn, P. J. H., Parker, A. J., Denton, R., & Riley, R. J. (2007) · Xenobiotica · doi:10.3109/00498250701557266 · Cited by 65
The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide
Töllner, K., Brandt, C., Römermann, K., & Löscher, W. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.019 · Cited by 62
Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach
Yeo, K. R., Jamei, M., & Rostami‐Hodjegan, A. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.4 · Cited by 63
Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine
Poirier, A., Funk, C., Scherrmann, J., & Lavé, T. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002495 · Cited by 61
Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast
Karonen, T., Filppula, A. M., Laitila, J., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.73 · Cited by 61
Investigation of Fluorescein Derivatives as Substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 To Develop Sensitive Fluorescence-Based OATP1B1 Inhibition Assays
Izumi, S., Nozaki, Y., Komori, T., Takenaka, O., Maeda, K., Kusuhara, H., & Sugiyama, Y. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00664 · Cited by 63
Self-citation
Transporters: Importance in Drug Absorption, Distribution, and Removal
Rüssel, F. G. M. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0840-7_2 · Cited by 59
Role of transport proteins in drug discovery and development: a pharmaceutical perspective
Ayrton, A. D., & Morgan, P. (2008) · Xenobiotica · doi:10.1080/00498250801923855 · Cited by 58
Bax-mediated mitochondrial outer membrane permeabilization (MOMP), distinct from the mitochondrial permeability transition, is a key mechanism in diclofenac-induced hepatocyte injury: Multiple protective roles of cyclosporin A
Siu, W. P., Pun, P. B. L., Latchoumycandane, C., & Boelsterli, U. A. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.11.030 · Cited by 58
Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion
Lai, Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903127234 · Cited by 57
The Eighth and Ninth Transmembrane Domains in Organic Anion Transporting Polypeptide 1B1 Affect the Transport Kinetics of Estrone-3-Sulfate and Estradiol-17β-D-glucuronide
Miyagawa, M., Maeda, K., Aoyama, A., & Sugiyama, Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.148411 · Cited by 56
Self-citation
Effect of Culture Time on the Basal Expression Levels of Drug Transporters in Sandwich-Cultured Primary Rat Hepatocytes
Tchaparian, E. H., Houghton, J. S., Uyeda, C., Grillo, M. P., & Jin, L. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039545 · Cited by 56

Authors: Shitara, Y., Sato, H., & Sugiyama, Y.
Affiliations: SHOWA Medical University (JP)
The University of Tokyo (JP)
ORCID: Sato, Hitoshi
Sugiyama, Yuichi
Venue: Annual Review of Pharmacology and Toxicology
Publisher: Annual Reviews
Published: 2005-09-22
Volume: 45
Issue: 1
Pages: 689-723
ISSN: 0362-1642 (ISSN-L)
1545-4304
DOI: 10.1146/annurev.pharmtox.44.101802.121444
OpenAlex: W2066382275
Cited by: 336
References: 199
Citations by year: 2026: 2 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 8 · 2019: 7 · 2018: 9 · 2017: 14 · 2016: 15 · 2015: 12 · 2014: 14 · 2013: 23 · 2012: 25
FWCI: 2.12
Type: journal article
Language: en
Open access: closed
Locations: The Annual Review of Pharmacology and Toxicology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
Keywords: drug-drug interactions, drug transporters, renal drug excretion, organic anion transporting polypeptides, organic anion transporters, transporter inhibitors, Ki values, substrate specificity, probenecid, cephalosporins, cyclosporine, rifampicin, drug-metabolizing enzymes
MeSH terms: Animals, Biliary Tract, Biological Transport, Drug Evaluation, Drug Interactions, Pharmaceutical Preparations, Humans, Kidney, Liver

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

EVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks